Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 63


Determinants of response and resistance to CAR T cell therapy.

Lesch S, Benmebarek MR, Cadilha BL, Stoiber S, Subklewe M, Endres S, Kobold S.

Semin Cancer Biol. 2019 Nov 6. pii: S1044-579X(19)30219-6. doi: 10.1016/j.semcancer.2019.11.004. [Epub ahead of print] Review.


Challenges in Clinical Trial Design for T Cell-Based Cancer Immunotherapy.

Kruger SF, Cadilha BL, von Bergwelt-Baildon M, Endres S, Kobold S.

Clin Pharmacol Ther. 2019 Nov 9. doi: 10.1002/cpt.1659. [Epub ahead of print] No abstract available.


Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer.

Metzger P, Kirchleitner SV, Kluge M, Koenig LM, Hörth C, Rambuscheck CA, Böhmer D, Ahlfeld J, Kobold S, Friedel CC, Endres S, Schnurr M, Duewell P.

J Immunother Cancer. 2019 Nov 6;7(1):288. doi: 10.1186/s40425-019-0778-7.


Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox.

Kruger S, Schirle K, Haas M, Crispin A, Schirra J, Mayerle J, D'Haese JG, Kunz WG, Ricke J, Ormanns S, Kirchner T, Kobold S, Ilmer M, Gebauer L, Westphalen CB, von Bergwelt-Baildon M, Werner J, Heinemann V, Boeck S.

J Cancer Res Clin Oncol. 2019 Oct 23. doi: 10.1007/s00432-019-03061-4. [Epub ahead of print]


P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation.

Darowski D, Jost C, Stubenrauch K, Wessels U, Benz J, Ehler A, Freimoser-Grundschober A, Brünker P, Mössner E, Umaña P, Kobold S, Klein C.

Protein Eng Des Sel. 2019 Sep 3. pii: gzz027. doi: 10.1093/protein/gzz027. [Epub ahead of print]


Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy.

Karches CH, Benmebarek MR, Schmidbauer ML, Kurzay M, Klaus R, Geiger M, Rataj F, Cadilha BL, Lesch S, Heise C, Murr R, Vom Berg J, Jastroch M, Lamp D, Ding J, Duewell P, Niederfellner G, Sustmann C, Endres S, Klein C, Kobold S.

Clin Cancer Res. 2019 Oct 1;25(19):5890-5900. doi: 10.1158/1078-0432.CCR-18-3927. Epub 2019 Jul 8.


Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis.

Liu X, Li J, Cadilha BL, Markota A, Voigt C, Huang Z, Lin PP, Wang DD, Dai J, Kranz G, Krandick A, Libl D, Zitzelsberger H, Zagorski I, Braselmann H, Pan M, Zhu S, Huang Y, Niedermeyer S, Reichel CA, Uhl B, Briukhovetska D, Suárez J, Kobold S, Gires O, Wang H.

Sci Adv. 2019 Jun 19;5(6):eaav4275. doi: 10.1126/sciadv.aav4275. eCollection 2019 Jun.


Advances in cancer immunotherapy 2019 - latest trends.

Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M.

J Exp Clin Cancer Res. 2019 Jun 19;38(1):268. doi: 10.1186/s13046-019-1266-0. Review.


Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy.

Stoiber S, Cadilha BL, Benmebarek MR, Lesch S, Endres S, Kobold S.

Cells. 2019 May 17;8(5). pii: E472. doi: 10.3390/cells8050472. Review.


Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.

Darowski D, Kobold S, Jost C, Klein C.

MAbs. 2019 May/Jun;11(4):621-631. doi: 10.1080/19420862.2019.1596511. Epub 2019 Apr 17.


Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells.

Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S.

Int J Mol Sci. 2019 Mar 14;20(6). pii: E1283. doi: 10.3390/ijms20061283. Review.


Innate Immune Stimulation in Cancer Therapy.

Düwell P, Heidegger S, Kobold S.

Hematol Oncol Clin North Am. 2019 Apr;33(2):215-231. doi: 10.1016/j.hoc.2018.12.002. Epub 2019 Jan 9. Review.


Inflammation: a common contributor to cancer, aging, and cardiovascular diseases-expanding the concept of cardio-oncology.

Libby P, Kobold S.

Cardiovasc Res. 2019 Apr 15;115(5):824-829. doi: 10.1093/cvr/cvz058.


Enhancing tumor T cell infiltration to enable cancer immunotherapy.

Zhang J, Endres S, Kobold S.

Immunotherapy. 2019 Feb;11(3):201-213. doi: 10.2217/imt-2018-0111.


Innate and adaptive immunity combined for cancer treatment.

Kobold S.

Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1087-1088. doi: 10.1073/pnas.1820166116. Epub 2018 Dec 17. No abstract available.


Microphthalmia-Associated Transcription Factor (MITF) Regulates Immune Cell Migration into Melanoma.

Wiedemann GM, Aithal C, Kraechan A, Heise C, Cadilha BL, Zhang J, Duewell P, Ballotti R, Endres S, Bertolotto C, Kobold S.

Transl Oncol. 2019 Feb;12(2):350-360. doi: 10.1016/j.tranon.2018.10.014. Epub 2018 Nov 28.


High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy.

Rataj F, Jacobi SJ, Stoiber S, Asang F, Ogonek J, Tokarew N, Cadilha BL, van Puijenbroek E, Heise C, Duewell P, Endres S, Klein C, Kobold S.

Br J Cancer. 2019 Jan;120(1):79-87. doi: 10.1038/s41416-018-0341-1. Epub 2018 Nov 15.


Teaching an old dog new tricks: next-generation CAR T cells.

Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S.

Br J Cancer. 2019 Jan;120(1):26-37. doi: 10.1038/s41416-018-0325-1. Epub 2018 Nov 9. Review.


Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.

Herrmann M, Krupka C, Deiser K, Brauchle B, Marcinek A, Ogrinc Wagner A, Rataj F, Mocikat R, Metzeler KH, Spiekermann K, Kobold S, Fenn NC, Hopfner KP, Subklewe M.

Blood. 2018 Dec 6;132(23):2484-2494. doi: 10.1182/blood-2018-05-849802. Epub 2018 Oct 1.


PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.

Rataj F, Kraus FBT, Chaloupka M, Grassmann S, Heise C, Cadilha BL, Duewell P, Endres S, Kobold S.

Front Immunol. 2018 Aug 30;9:1955. doi: 10.3389/fimmu.2018.01955. eCollection 2018.

Supplemental Content

Loading ...
Support Center